Hexarelin is a synthetic hexapeptide categorized as a potent growth hormone secretagogue and selective agonist of the growth hormone secretagogue receptor (GHS-R1a). Designed strictly for laboratory research, this compound serves as a critical tool for investigating neuroendocrine pathways, pituitary somatotroph signaling, and receptor-mediated cellular responses.
Hexarelin is a synthetic hexapeptide categorized as a potent growth hormone secretagogue and selective agonist of the growth hormone secretagogue receptor (GHS-R1a). Designed strictly for laboratory research, this compound serves as a critical tool for investigating neuroendocrine pathways, pituitary somatotroph signaling, and receptor-mediated cellular responses.
Hexarelin is a synthetic six-amino-acid peptide (hexapeptide) belonging to the growth hormone secretagogue class. It mimics the signal transduction of endogenous ghrelin by selectively binding to the ghrelin receptor (GHS-R1a) to induce growth hormone release in pituitary cell models. Designed for institutional researchers seeking hexarelin peptide kopen, this reagent is restricted strictly to in vitro assays and preclinical animal research.
Discovered during studies aimed at optimizing short-chain synthetic peptide secretagogues, Hexarelin (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) exhibits high metabolic stability and potent receptor binding affinity. Preclinical literature demonstrates that its structural configuration confers resistance to rapid enzymatic cleavage compared to endogenous ghrelin, making it a valuable candidate for mapping pituitary response kinetics and downstream metabolic cascades.
The primary structure of Hexarelin incorporates unnatural D-amino acids within its hexapeptide backbone. This design prevents rapid hydrolysis by ubiquitous circulating peptidases, providing a prolonged biological half-life in laboratory incubation assays. With a molecular formula of C47H58N12O6 and a molecular weight of approximately 887.04 g/mol, the peptide exhibits excellent solubility in aqueous solutions under controlled laboratory conditions.
In analytical evaluations, Hexarelin displays distinct structural stability across a broad pH range. However, exposure to strong oxidizing environments or extreme heat can lead to structural modification. Researchers studying growth hormone secretagogues utilize Hexarelin to observe how chemical modification of the N-terminus alters receptor binding dynamics relative to natural ligands.
The primary mechanism of Hexarelin involves binding to the central and peripheral ghrelin receptor (GHS-R1a), a G-protein coupled receptor (GPCR) predominantly expressed in the anterior pituitary gland and hypothalamus. Upon receptor ligation, Hexarelin activates the phospholipase C (PLC) signaling pathway, causing a downstream increase in intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG).
This signaling event prompts the rapid mobilization of intracellular calcium ions from the endoplasmic reticulum into the cytoplasm. Preclinical models demonstrate that this transient calcium flux triggers exocytosis of growth-hormone-containing vesicles from somatotrophic cells. Unlike growth hormone-releasing hormone (GHRH), which operates via cyclic adenosine monophosphate (cAMP) pathways, Hexarelin stimulates secretion through this distinct, calcium-dependent signal transduction network.
In vitro studies utilizing primary rat pituitary cell cultures show that Hexarelin stimulates somatotroph degranulation in a concentration-dependent manner. Researchers frequently use Hexarelin to quantify secretagogue potency, evaluate receptor desensitization thresholds, and analyze crosstalk between GHRH and GHS-R signaling pathways.
In animal models, including rodent and canine subjects, administration of Hexarelin results in robust pulsatile growth hormone secretion. Preclinical data indicate that simultaneous co-incubation with GHRH produces a synergistic release of growth hormone, suggesting dual-site activation of independent pituitary membrane receptors. Furthermore, research models investigate how chronic exposure to Hexarelin leads to GHS-R1a receptor internalisation, providing insight into receptor down-regulation mechanisms.
Beyond its classical endocrine activity via GHS-R1a, Hexarelin exhibits affinity for the scavenger receptor CD36, which is abundantly expressed in cardiac tissue, microvascular endothelial cells, and macrophages. Preclinical cardiac models demonstrate that Hexarelin binding to CD36 influences lipid metabolism, cellular stress responses, and ischemic recovery mechanisms independent of pituitary growth hormone release.
In isolated perfused heart preparations and rodent models of myocardial ischemia-reperfusion injury, Hexarelin administration has been observed to attenuate cardiac tissue apoptosis, decrease infarct size, and support hemodynamic parameters. These findings suggest that Hexarelin's structural features engage non-somatotrophic receptor targets, making it a valuable research tool in cardiovascular biology and ischemia research.
When evaluating synthetic secretagogues, researchers frequently compare Hexarelin to related analogs within the growth hormone-releasing peptide (GHRP) family. While all members share an affinity for GHS-R1a, their potency profiles, receptor selectivities, and secondary endocrine impacts differ significantly.
Compared to Ipamorelin, which is celebrated for its extreme receptor selectivity and minimal impact on secondary hormones, Hexarelin exhibits higher raw potency for somatotroph stimulation. However, high-concentration assays reveal that Hexarelin may induce modest transient elevations in cortisol and prolactin levels, similar to GHRP-2 and GHRP-6. Additionally, Hexarelin displays unique CD36 binding kinetics that are absent or significantly diminished in Ipamorelin, positioning Hexarelin as the preferred compound for dual cardiovascular and somatotrophic research protocols.
Proper reconstitution is critical to maintaining the structural integrity of Hexarelin and ensuring reproducible experimental results. Reconstitution should always be conducted within a certified laminar flow hood using sterile, aseptic techniques to prevent microbial contamination.
Researchers typically reconstitute lyophilized Hexarelin powder using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl), depending on the requirements of the specific assay system. For detailed volumetric calculations and concentration adjustments, investigators can consult our standard reconstitution protocols. The solvent should be gently introduced along the inner glass wall of the vial, followed by gentle swirling. Mechanical agitation or vigorous shaking must be avoided, as shear forces can cause peptide denaturation or aggregation.
Lyophilized Hexarelin is highly stable when stored under proper environmental conditions. Upon receipt, unopened vials should be kept in a climate-controlled freezer at -20°C for short-to-medium-term storage, or at -80°C for extended stability up to 24 months. Desiccant should be present in the storage container to protect the powder from moisture ingress.
Once reconstituted into solution, Hexarelin should be refrigerated at 2°C to 8°C and utilized within 28 days to prevent hydrolysis or chemical degradation. Reconstituted aliquots intended for future use should be frozen immediately at -80°C to avoid repeated freeze-thaw cycles, which compromise structural fidelity. Detailed handling procedures are outlined in our comprehensive research catalog.
To guarantee valid and reproducible scientific outcomes, laboratory reagents must adhere to strict analytical purity benchmarks. PX1 Research validates every lot of Hexarelin through rigorous physical and chemical testing conducted by accredited third-party analytical laboratories.
Purity assessment is performed using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum chemical purity of 99%. Identity confirmation is verified via Electrospray Ionization Mass Spectrometry (ESI-MS), matching the observed molecular weight against theoretical values. Furthermore, quantitative bacterial endotoxin testing (LAL assay) confirms levels strictly below defined thresholds (<0.01 EU/mg), ensuring compatibility with sensitive cell cultures. Detailed documentation for each batch is accessible via our analytical testing standards hub.
Selecting a reliable supplier for research chemicals requires strict adherence to quality verification, manufacturing transparency, and chain-of-custody control. PX1 Research manufactures all compounds within modern, GMP-compliant facilities located in the United States, upholding ISO 17025 laboratory standards.
Institutional facilities seeking hexarelin peptide kopen receive fully verified, lot-traceable reagents accompanied by batch-specific Certificates of Analysis (COA). PX1 Research ships directly from facilities in California and Arizona, offering same-day dispatch (Monday through Friday) to ensure rapid delivery without compromising thermal stability. Qualified academic and corporate entities requiring scaled quantities can access our streamlined purchasing channels via the PX1 Research wholesale portal.
What is the primary scientific application of Hexarelin?
Hexarelin is primarily used in preclinical and in vitro research to investigate GHS-R1a receptor binding dynamics, pituitary somatotroph secretagogue signaling pathways, intracellular calcium mobilization, and non-endocrine CD36 receptor interactions.
How does Hexarelin differ from native ghrelin?
Unlike native ghrelin, which is a 28-amino-acid acylated peptide, Hexarelin is a synthetic hexapeptide containing unnatural D-amino acids. This modifications grants Hexarelin higher metabolic stability and resistance to enzymatic cleavage in experimental models.
What purity standard is guaranteed for Hexarelin from PX1 Research?
Every batch of Hexarelin supplied by PX1 Research undergoes independent third-party verification, maintaining a minimum purity of 99% as confirmed by RP-HPLC and ESI-MS mass spectrometry analysis.
How should reconstituted Hexarelin be stored in the laboratory?
After reconstitution with sterile bacteriostatic water or saline, Hexarelin solutions should be stored at 2°C to 8°C and used within 28 days. For long-term storage of reconstituted solutions, single-use aliquots should be frozen at -80°C to prevent degradation from repeated freeze-thaw cycles.
What is the endotoxin limit for PX1 Research Hexarelin?
PX1 Research subjects all peptide lots to Chromogenic LAL endotoxin testing. Hexarelin lots are confirmed to contain less than 0.01 EU/mg of bacterial endotoxins, making them safe for sensitive cell culture and in vitro assays.
Does Hexarelin activate receptors other than the ghrelin receptor?
Yes. In addition to being a potent GHS-R1a agonist, preclinical studies demonstrate that Hexarelin binds to the scavenger receptor CD36, making it a key subject in cardiovascular tissue and ischemic recovery research.
Is Hexarelin approved for human clinical administration or therapy?
No. Hexarelin is strictly synthesized and sold for laboratory research, in vitro experimentation, and preclinical scientific study. It is not intended or approved for human consumption, therapeutic use, or clinical administration.
How can researchers access the Certificate of Analysis (COA) for Hexarelin?
Every shipment from PX1 Research includes lot-specific identifiers that allow researchers to view and download the corresponding third-party RP-HPLC and Mass Spectrometry COAs directly from our online database.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.